Home - Products - Others - Other Targets - 6-Hydroxy-7-methoxydihydroligustilide

6-Hydroxy-7-methoxydihydroligustilide

CAS No. 210036-09-2

6-Hydroxy-7-methoxydihydroligustilide( —— )

Catalog No. M32197 CAS No. 210036-09-2

6-Hydroxy-7-methoxydihydroligustilide is a natural product for research related to life sciences.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 270 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    6-Hydroxy-7-methoxydihydroligustilide
  • Note
    Research use only, not for human use.
  • Brief Description
    6-Hydroxy-7-methoxydihydroligustilide is a natural product for research related to life sciences.
  • Description
    6-Hydroxy-7-methoxydihydroligustilide is a natural product for research related to life sciences.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    210036-09-2
  • Formula Weight
    238.3
  • Molecular Formula
    C13H18O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • (Phe22)-Big Endothel...

    (Phe22)-Big Endothelin-1 fragment (19-37) (human)

  • RMC-7977

    RMC-7977 is a highly selective inhibitor of the active (GTP-bound) forms of KRAS, HRAS, and NRAS with anticancer activity for the study of solid tumors with KRAS G12C mutations.

  • Remimazolam

    Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?